COYA Latest Press Releases

-- October 28, 2026 --

Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting Business Wire 8:00 AM

-- October 14, 2026 --

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS Business Wire 8:00 AM

-- October 13, 2026 --

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference Business Wire 8:00 AM

-- October 5, 2026 --

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire 8:00 AM

-- September 15, 2026 --

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire 8:00 AM

-- September 8, 2026 --

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation Business Wire 8:00 AM

-- June 18, 2026 --

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting Business Wire 8:00 AM

-- June 15, 2026 --

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease Business Wire 8:00 AM

-- June 8, 2026 --

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Business Wire 8:00 AM

Market Data Delayed 15 Minutes